Compare · AZRX vs FLXN
AZRX vs FLXN
Side-by-side comparison of AzurRx BioPharma, Inc. (AZRX) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZRX and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN is the larger of the two at $458.9M, about 13.3x AZRX ($34.4M).
- FLXN has more recent analyst coverage (7 ratings vs 1 for AZRX).
- Company
- AzurRx BioPharma, Inc.
- Flexion Therapeutics, Inc.
- Price
- $3.46+2.67%
- $25.11-0.20%
- Market cap
- $34.4M
- $458.9M
- 1M return
- -
- -0.20%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 7
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest AZRX
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
- SEC Form 4 filed by Coelho Mary Theresa
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma Announces Reverse Stock Split
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)